ST
ACHN

Spot Trading’s Achillion Pharmaceuticals ACHN Stock Holding History

Spot Trading’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-40,000
Closed -$324K – 3369
2016
Q3 		$324K Buy
+40,000
New +$340K 0.01% 1775
2016
Q1 		– Sell
-86,300
Closed -$931K – 4232
2015
Q4 		$931K Sell
86,300
-1,900
-2% -$17.3K 0.01% 1505
2015
Q3 		$609K Buy
88,200
+85,900
+3,735% +$700K 0.01% 1913
2015
Q2 		$20K Buy
+2,300
New +$21.8K ﹤0.01% 3470
2015
Q1 		– Sell
-326,600
Closed -$4M – 4503
2014
Q4 		$4M Buy
326,600
+222,600
+214% +$2.72M 0.03% 941
2014
Q3 		$1.04M Buy
104,000
+3,500
+3% +$32.5K 0.01% 2056
2014
Q2 		$761K Buy
+100,500
New +$401K ﹤0.01% 2351
2014
Q1 		– Sell
-93,400
Closed -$310K – 4650
2013
Q4 		$310K Sell
93,400
-98,100
-51% -$285K ﹤0.01% 2772
2013
Q3 		$578K Buy
191,500
+164,100
+599% +$1.12M ﹤0.01% 2339
2013
Q2 		$224K Buy
+27,400
New +$209K ﹤0.01% 2973

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Spot Trading's ACHN Position: Q4 2016 in Review

Spot Trading sold out of Achillion Pharmaceuticals (ACHN) in Q4 2016, closing a stake of 4,836 shares — an estimated $39K sold.

Spot Trading first reported a position in ACHN in Q3 2013 and held it in 7 quarters. The position peaked at $343K in Q3 2014. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • Spot Trading reported no remaining Achillion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Spot Trading sold 4,836 Achillion Pharmaceuticals shares in Q4 2016, an estimated $39K.
  • Spot Trading first reported a position in Achillion Pharmaceuticals in Q3 2013 and held it in 7 quarters.
  • Spot Trading's Achillion Pharmaceuticals position peaked at $343K in Q3 2014.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on Spot Trading's 13F filing for Q4 2016, filed 7 Feb 2017.